- Another humbling scientific failure to improve mild/moderate Alzheimer’s Disease in a large, phase 3 clinical trial. Merck’s BACE1-inhibitor: reduced amyloid breakdown product by up to 80%, but failed to improve mental outcomes or any other clinical endpoint. https://www.nejm.org/doi/full/10.1056/nejmoa1706441 68 comments science
- A large, randomized phase 3 trial of a BACE-inhibitor for mild to moderate Alzheimer’s Disease fails. No signal on any of the major clinical endpoints or in any of the meaningful subgroups. https://www.nejm.org/doi/full/10.1056/nejmoa1706441 4 comments science
Linked pages
Related searches:
Search whole site: site:www.nejm.org
Search title: Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease | NEJM
See how to search.